[go: up one dir, main page]

CU23000A1 - VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY - Google Patents

VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY

Info

Publication number
CU23000A1
CU23000A1 CU20000285A CU20000285A CU23000A1 CU 23000 A1 CU23000 A1 CU 23000A1 CU 20000285 A CU20000285 A CU 20000285A CU 20000285 A CU20000285 A CU 20000285A CU 23000 A1 CU23000 A1 CU 23000A1
Authority
CU
Cuba
Prior art keywords
vaccine compositions
receptors
cancer
specific active
gangliosides
Prior art date
Application number
CU20000285A
Other languages
Spanish (es)
Inventor
Ramirez Belinda Sanchez
Pestana Eduardo Raul Suarez
Acosta Anabel Alvarez
Molina Luis Enrique Fernandez
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU20000285A priority Critical patent/CU23000A1/en
Priority to PE2001001202A priority patent/PE20020572A1/en
Priority to ARP010105662A priority patent/AR031638A1/en
Priority to MYPI20015558 priority patent/MY129626A/en
Priority to CA2431188A priority patent/CA2431188C/en
Priority to DE60143363T priority patent/DE60143363D1/en
Priority to KR1020037007634A priority patent/KR100850473B1/en
Priority to EA200300640A priority patent/EA005138B1/en
Priority to ES01999387T priority patent/ES2353857T3/en
Priority to AT01999387T priority patent/ATE485833T1/en
Priority to US10/003,463 priority patent/US7776342B2/en
Priority to EP01999387A priority patent/EP1356822B1/en
Priority to JP2002547529A priority patent/JP4210519B2/en
Priority to UY27059A priority patent/UY27059A1/en
Priority to AU2002221519A priority patent/AU2002221519B2/en
Priority to HK04106497.1A priority patent/HK1063726B/en
Priority to PCT/CU2001/000010 priority patent/WO2002045746A2/en
Priority to MXPA03005032A priority patent/MXPA03005032A/en
Priority to DK01999387.2T priority patent/DK1356822T3/en
Priority to BR0116013-3 priority patent/BRPI0116013B8/en
Priority to CNB018215602A priority patent/CN1291755C/en
Priority to AU2151902A priority patent/AU2151902A/en
Priority to NZ526282A priority patent/NZ526282A/en
Priority to ZA200304411A priority patent/ZA200304411B/en
Publication of CU23000A1 publication Critical patent/CU23000A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención está relacionada con el campo de la inmunoterapia activa específica del cáncer y en particular con la obtención de composiciones vacunales para la inducir o incrementar la respuesta inmune contra receptores de factores de crecimiento autólogos que estén sobre expreexpresados en la membrana de algunos tipos de tumores y que están vinculados con el crecimiento tumoral. Dichas composiciones contienen receptores de factores de crecimiento con actividad tirosina quinasa, o alternativamente sus variantes que comprenden el dominio extracelular de dichos receptores con y sin región transmembrana, unidos a proteoliposomas de muy baja talla con gangliósidos incorporados (siglas en inglés, VSSP-G), siendo dichos gangliósidos los que se asocian específicamente a los receptores en forma de agrupaciones moleculares de membrana, y empleándose en adyuvante apropiado. La presente invención además se relaciona con el uso e las composiciones vacunales para la prevención y tratamiento del cáncer, particularmente cáncer de próstata, colon, pulmón, mama, ovario, cabeza-cuello, vulva, vejiga, gliomas, así como en enfermedades crónicas no trasmisibles.The present invention is related to the field of cancer-specific active immunotherapy and in particular to obtaining vaccine compositions for inducing or increasing the immune response against autologous growth factor receptors that are overexpressed on the membrane of some types of tumors and that are linked to tumor growth. Said compositions contain growth factor receptors with tyrosine kinase activity, or alternatively their variants comprising the extracellular domain of said receptors with and without transmembrane region, linked to very small size proteoliposomes with incorporated gangliosides (VSSP-G) , said gangliosides being those that are specifically associated with the receptors in the form of molecular membrane clusters, and used in appropriate adjuvant. The present invention also relates to the use of vaccine compositions for the prevention and treatment of cancer, particularly prostate cancer, colon, lung, breast, ovary, head-neck, vulva, bladder, gliomas, as well as chronic diseases. transmissible.

CU20000285A 2000-12-06 2000-12-06 VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY CU23000A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (en) 2000-12-06 2000-12-06 VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY
PE2001001202A PE20020572A1 (en) 2000-12-06 2001-11-29 PREPARATIONS TO ENHANCE THE IMMUNOGENICITY OF UNIMMUNOGENIC ANTIGENS
ARP010105662A AR031638A1 (en) 2000-12-06 2001-12-05 PHARMACEUTICAL COMPOSITIONS TO POWER THE IMMUNOGENICITY OF LITTLE IMMUNOGENIC ANTIGENS
MYPI20015558 MY129626A (en) 2000-12-06 2001-12-05 Preparations that potentiate immunogenicity in low immunogenic antigens
CA2431188A CA2431188C (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
DE60143363T DE60143363D1 (en) 2000-12-06 2001-12-06 PHARMACEUTICAL COMPOSITIONS THAT PROMOTE THE IMMUNOGENICITY OF WEAK IMMUNOGENIC ANTIGENES
KR1020037007634A KR100850473B1 (en) 2000-12-06 2001-12-06 A pharmaceutical composition for improving immunogenicity of an antigen having poor immunogenicity
EA200300640A EA005138B1 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
ES01999387T ES2353857T3 (en) 2000-12-06 2001-12-06 PHARMACEUTICAL COMPOSITIONS THAT IMPROVE THE IMMUNOGENICITY OF LITTLE IMMUNOGENIC ANTIGENS.
AT01999387T ATE485833T1 (en) 2000-12-06 2001-12-06 PHARMACEUTICAL COMPOSITIONS THAT PROMOTE THE IMMUNOGENICITY OF WEAKLY IMMUNOGENIC ANTIGENS
US10/003,463 US7776342B2 (en) 2000-12-06 2001-12-06 Preparations that potentiate immunogenicity in low immunogenic antigens
EP01999387A EP1356822B1 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
JP2002547529A JP4210519B2 (en) 2000-12-06 2001-12-06 Pharmaceutical composition for enhancing the immunogenicity of a low immunogenic antigen
UY27059A UY27059A1 (en) 2000-12-06 2001-12-06 PREPARATIONS TO POWER THE IMMUNOGENCITY OF LITTLE IMMUNOGENIC ANTIGENS
AU2002221519A AU2002221519B2 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
HK04106497.1A HK1063726B (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
PCT/CU2001/000010 WO2002045746A2 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
MXPA03005032A MXPA03005032A (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens.
DK01999387.2T DK1356822T3 (en) 2000-12-06 2001-12-06 Pharmaceutical compositions that enhance the immunogenicity of weakly immunogenic antigens
BR0116013-3 BRPI0116013B8 (en) 2000-12-06 2001-12-06 pharmaceutical composition to enhance the immunogenicity of poorly immunogenic antigens, and use of pharmaceutical composition
CNB018215602A CN1291755C (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2151902A AU2151902A (en) 2000-12-06 2001-12-06 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
NZ526282A NZ526282A (en) 2000-12-06 2003-06-04 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
ZA200304411A ZA200304411B (en) 2000-12-06 2003-06-05 Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (en) 2000-12-06 2000-12-06 VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY

Publications (1)

Publication Number Publication Date
CU23000A1 true CU23000A1 (en) 2004-10-12

Family

ID=43607757

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000285A CU23000A1 (en) 2000-12-06 2000-12-06 VACCINE COMPOSITIONS FOR CANCER SPECIFIC ACTIVE IMMUNOTHERAPY

Country Status (2)

Country Link
CU (1) CU23000A1 (en)
ES (1) ES2353857T3 (en)

Also Published As

Publication number Publication date